期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Low-level viremia in nucleoside analog-treated chronic hepatitis B patients 被引量:12
1
作者 Qian Zhang da-chuan cai +1 位作者 Peng Hu Hong Ren 《Chinese Medical Journal》 SCIE CAS CSCD 2021年第23期2810-2817,共8页
Low-level viremia(LLV)was defined as persistent or intermittent episodes of detectable hepatitis B virus(HBV)DNA(<2000 IU/mL,detection limit of 10 IU/mL)after 48 weeks of antiviral treatment.Effective antiviral the... Low-level viremia(LLV)was defined as persistent or intermittent episodes of detectable hepatitis B virus(HBV)DNA(<2000 IU/mL,detection limit of 10 IU/mL)after 48 weeks of antiviral treatment.Effective antiviral therapies for chronic hepatitis B(CHB)patients,such as entecavir(ETV),tenofovir disoproxil fumarate(TDF),and tenofovir alafenamide(TAF),have been shown to inhibit the replication of HBV DNA and prevent liver-related complications.However,even with long-term antiviral therapy,there are still a number of patients with persistent or intermittent LLV.At present,the research on LLV to address whether adversely affect the clinical outcome is limited,and the follow-up treatment for these patients is open to question.At the same time,the mechanism of LLV is not clear.In this review,we summarize the incidence of LLV,the association between LLV and long-term outcomes,possible mechanisms,and management strategies in these patient populations. 展开更多
关键词 Chronic hepatitis B Nucleoside/nucleotide analog treatment Low-level viremia Long-term outcomes
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部